Enveric Biosciences, Inc. · NASDAQ:ENVB
Enveric Biosciences — Investor Presentation (June 2026)
15 slides from Enveric Biosciences's investor presentation, Jun 9, 2026
Slide 1: Driving Innovation in Mental Health Therapeutics
:ENVB TM NEXT GENERATION MENTAL HEALTH Q2 2026 | CORPORATE PRESENTATION Driving Innovation in Mental Health Therapeutics Enveric.com
Slide 2: Disclaimer
Disclaimer No Offer or Solicitation This communication is for informational purposes only and is not intended to and does not constitute an offer to sell, or the solicitation of an offer to buy any securities or a solicitation of any vote or approval. It does not constitute a prospectus or prospectu
Slide 3: Neuroplastogens Redefining the Next Wave of Psychiatric Treatment
:ENVB Neuroplastogens Redefining the Next Wave of Psychiatric Treatment Emerging psychedelic and non-hallucinogenic compounds are demonstrating the potential to drive rapid neural plasticity and transform treatment paradigms. Psychiatry Faces a Major Neuroplastogens May Enable Enveric’s Differentiat
Slide 4: Significant Market Opportunities Across Neuropsychiatry
:ENVB Significant Market Opportunities Across Neuropsychiatry 3.5+ $ 90+ BILLION Patients Across Target Indications * $ BILLION Total Addressable Market ** PTSD DEPRESSION ANXIETY ADDICTION OCD MIGRAINE Many patients remain inadequately treated in multiple indications *Source: NIH, WHO, WHO, WHO, WH
Slide 5: The Current Treatment Paradigm
The Current Treatment Paradigm More than 150 FDA-approved drugs are currently used to treat psychiatric disorders. Diagnosis Start Limited Early Symptom Dose Adjustments Ongoing Chronic Treatment Improvement Therapy Day 1 Day 1 Weeks-Months Months - Years Indefinite Meaningful Limitations Remain o M
Slide 6: Neuroplastogens: A New Class of Drugs
:ENVB Neuroplastogens: A New Class of Drugs Promotes neuroplasticity in Prefrontal Cortex (PFC) and restores normal function Prefrontal Cortex The Healthy Brain Dynamic coordination between the PFC and the limbic system regulates emotional responses1 Neuroplastogens Neuropsychiatric Disorders These
Slide 7: Big Pharma Validation of Neuroplastogen Hypothesis
Big Pharma Validation of Neuroplastogen Hypothesis Neuroplasticity: new treatment paradigm for neuropsychiatry Recent Acquisitions $1.2 B acquisition* of Bretisilocin • On Phase 2A completion * $900 M upfront $1.225 B acquisition** • On Phase 2 completion ** $700 M upfront :ENVB
Slide 8: Non-hallucinogenic Neuroplastogens: Potential Advantage Over Psychedelics
Non-hallucinogenic Neuroplastogens: Potential Advantage Over Psychedelics Psychedelics Potential Advantage Non-hallucinogenic neuroplastogens ⚬Access to much larger treatable patient population ⚬Chronic or repeat administration ⚬Lower regulatory and commercialization friction ⚬Stronger compatibility
Slide 9: EB-003: Dual 5-HT2A Partial Agonist & 5-HT1B Agonist
:ENVB EB-003: Dual 5-HT2A Partial Agonist & 5-HT1B Agonist Partial 5-HT2A agonism may promote cortical plasticity, while 5-HT1B agonism may stabilize subcortical circuits, reducing anxiety and depression symptoms1. Together, they may enable the brain to learn, adapt, and maintain healthier patterns
Slide 10: Target Product Profile
:ENVB Target Product Profile Novel, non-hallucinogenic neuroplastogen for the EB-003 treatment of neuropsychiatric disorders Indication(s) MDD, GAD, PTSD, TRD Patient population Adults Mechanism of action 5-HT2A partial agonist and 5-HT1B full agonist Modality Small molecule DMT analog Administratio
Slide 11: Data Supporting Target Product Profile
:ENVB Data Supporting Target Product Profile ü Mouse: head-twitch response results ü Mouse: monitored during oral PK study – no observed effects ü Rat: monitored during oral PK study – no observed effects ü Dog: monitored during oral PK study – no observed effects Non-hallucinogenic ü DRF showed no
Slide 12: EB-003 Program Timeline Through Phase 1B
:ENVB EB-003 Program Timeline Through Phase 1B 2026 2027 2028 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q CMC for Phase 1 trials CMC for Phase 2 trials Ongoing MoA studies (non-IND-enabling) IND Prep & Submission IND Top Line Phase 1A Top Line Phase 1B IND-Enabling GLP Studies Phase 1A Phase 1B To IND Filin
Slide 13: Enveric Pipeline
:ENVB Enveric Pipeline Milestone Stage Partner / Licensee Payments Available for Partnering Partner EB-003 & EVM301 Series Neuroplastogens Preclinical EVM401 Series Neuroplastogens Discovery Out-Licensed Licensee EB-002 & EVM201 Series Psilocin Prodrugs Preclinical MycoMedica Life Sciences $62 Milli
Slide 14: Management
:ENVB Management Management Team Board of Directors Scientific Advisors Joseph Tucker, Ph.D. Michael D. Webb Maurizio Fava, M.D. Chief Executive Officer Board Chair Scientific Advisor & Director George Kegler Stephen M. Stahl, M.D. Director, Chair of the Audit Committee Scientific Advisor Kevin Cove
Slide 15: :ENVB
Nasdaq :ENVB Mental Health™ BIlOS CIENCES Enveric.com
Enveric Biosciences — Investor Presentation (June 2026) on 6ix